The weight-loss drug gold rush is getting larger

More drug companies are racing to join what's been a two-horse race to make blockbuster obesity drugs, snapping up smaller biotechs and vying for a market that could be worth tens of billions in less than a decade. Why it matters: GLP-1 agonists like Novo Nordisk's Wegovy and Ozempic have soared…#glp1 #novonordisk #wegovyandozempic #medicare #zuercherkantonalbank #roche #carmottherapeutics #obese #carmot #astrazeneca
Source: Reuters: Health - Category: Consumer Health News Source Type: news